top of page

Polymotion IDE Study Achieves 85% Enrolment in 2025

  • JointMedica Admin
  • 5 hours ago
  • 2 min read

The Polymotion® Hip Resurfacing (PHR®) IDE study is closing out 2025 on a high note, having reached 85% enrolment. This milestone represents substantial progress toward study completion and reflects a successful year of steady recruitment across participating sites.


As enrolment advances toward its final phase, the study continues to demonstrate strong engagement from both surgeons and patients who are seeking modern, bone-conserving alternatives to total hip replacement.


ree

The Polymotion® Hip Resurfacing System is an investigational device designed for active patients seeking bone-conserving alternatives to traditional hip replacement. Unlike contemporary metal-on-metal technologies, the Polymotion® system combines a Vitamin E-infused polyethylene cup with a titanium-coated shell and a metal femoral cap — avoiding metal-on-metal articulation while maintaining excellent range of motion and implant stability.


The IDE study is currently active at the following clinical sites:

  • Mr. Ronan Treacy and Dr. Will Peckett – King Edward VII (Bermuda)

  • Dr. Thomas Gross and Dr. Coleman Fowble – Midlands Orthopaedics & Neurosurgery (Columbia, SC)

  • Dr. Stephen Raterman – Florida Medical Clinic Orlando Health (Tampa, FL)

  • Dr. William Macaulay, Dr. Scott Marwin, and Dr. Matthew Hepinstall – NYU Langone (New York, NY)

  • Dr. Craig Della Valle – Rush University Medical Center (Chicago, IL)

  • Dr. Michael Mont – Sinai Hospital (Baltimore, MD)

  • Dr. Anthony Carter – Hampton Roads Orthopaedics (Newport News, VA)

  • Dr. Thomas Huff – Oregon Health & Science University (Portland, OR)

  • Dr. David Crawford – Joint Implant Surgeons (New Albany, OH)


We are grateful to our investigators, study coordinators, and clinical partners for their continued dedication. Their efforts have been instrumental in advancing enrolment and supporting patient access to alternative resurfacing options—particularly for younger, active patients, including women and smaller-framed individuals.


JointMedica’s Chief Commercial Officer, Tim Band, stated:

“Achieving 85% enrolment by the end of 2025 is a meaningful accomplishment and a reflection of the confidence placed in the Polymotion® system by our clinical partners. We appreciate the commitment of every surgeon and patient involved and look forward to completing enrolment as the study continues into 2026.”


With strong momentum carrying into the new year, the team is focused on completing enrolment and advancing the study through its next stages in 2026.


For More Information

To learn more about the Polymotion® Hip Resurfacing System and the IDE study, please contact: cs@jointmedica.com

 
 
 
bottom of page